Zimmer Biomet Holdings (ZBH) EBITDA (2009 - 2026)

Zimmer Biomet Holdings has reported EBITDA for 18 years, with the latest figure at $373.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 27.68% year-over-year to $373.2 million; the trailing twelve-month figure through Mar 2026 stood at $1.2 billion (down 10.14% YoY), and the FY2025 full-year result was $1.1 billion, down 14.59% from the prior year.
• EBITDA for Q1 2026 stood at $373.2 million, up from $154.5 million in the prior quarter.
• The five-year high for EBITDA was $389.0 million in Q4 2024, with the low at -$28.3 million in Q4 2022.
• Average EBITDA over 5 years is $278.3 million, with a median of $292.3 million recorded in 2025.
• Peak annual rise in EBITDA reached 2775.36% in 2022, while the deepest fall reached 121.15% in 2022.
• Tracing ZBH's EBITDA over 5 years: stood at -$28.3 million in 2022, then jumped by 1351.59% to $354.2 million in 2023, then increased by 9.82% to $389.0 million in 2024, then plunged by 60.28% to $154.5 million in 2025, then jumped by 141.55% to $373.2 million in 2026.
• The last three EBITDA figures came in at $373.2 million (Q1 2026), $154.5 million (Q4 2025), and $351.3 million (Q3 2025), per Business Quant data.

Peer Comparison